Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals
Purpose: The 340B Drug Pricing Program is a federal program designed to reduce the amount that safety net providers spend on outpatient drugs. The Patient Protection and Affordable Health Care Act of 2010 extended eligibility for 340B to critical access hospitals (CAHs) for all drugs except those de...
Saved in:
Main Authors: | Madeline Carpinelli Wallack (Author), Todd Sorensen, PharmD (Author) |
---|---|
Format: | Book |
Published: |
University of Minnesota Libraries Publishing,
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals
by: Madeline Carpinelli Wallack, et al.
Published: (2012) -
Extent of Drug Coverage across Generic Drug Discount Programs offered by Community Pharmacies: A look at five Chronic Conditions
by: Harshali K. Patel, MS, et al.
Published: (2012) -
International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
by: Eun Young Shin, et al.
Published: (2024) -
Delay discounting, probability discounting, and interdental cleaning frequency
by: Anthony DeFulio, et al.
Published: (2022) -
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023)